Lipidomic approaches to measuring isoprostanes and other markers of oxidative stress

European Journal of Lipid Science and Technology

Volumn 111, Issue 1, 2009, Pages 64-74

  Davies, Sean S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GC MS; Isoprostanes; LC MS; Lipid peroxidation; Oxidative stress

Indexed keywords

EID: 58949099722     PISSN: 14387697     EISSN: 14389312     Source Type: Journal    
DOI: 10.1002/ejlt.200800132     Document Type: Review

References (66)

1. M. B. Kadiiska, B. C. Gladen, D. D. Baird, D. Germolec et al.: Biomarkers of oxidative stress study II: Are oxidation products of lipids, proteins, and DNA markers of CCl(4) poisoning? Free Radic Biol Med. 2005, 38, 698-710.
2. J. D. Morrow, K. E. Hill, R. F. Burk, T. M. Nammour, K. F. Badr, L. J. Roberts 2nd: A series of prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990, 87, 9383-9387.
3. H. Yin, L. Gao, H.-H. Tai, L. J. Murphey, N. A. Porter, J. D. Morrow: Urinary prostaglandin F2alpha is generated from the isoprostane pathway and not the cyclooxygenase in humans. J Biol Chem. 2007, 282, 329-336.
4. D. Sun, C. D. Funk: Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein. J Biol Chem. 1996, 271, 24055-24062.
5. T. Cyrus, D. Pratico, L. Zhao, J. L. Witztum, D. J. Rader, J. Rokach, G. A. FitzGerald, C. D. Funk: Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation. 2001, 103, 2277-2282.
6. C. M. Chinnici, Y. Yao, T. Ding, C. D. Funk, D. Pratico: Absence of 12/15 lipoxygenase reduces brain oxidative stress in apolipoprotein E-deficient mice. Am J Pathol. 2005, 167, 1371-1377.
7. R. Zhang, M.-L. Brennan, Z. Shen, J. C. MacPherson, D. Schmitt, C. E. Molenda, S. L. Hazen: Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem. 2002, 277, 46116-46122.
8. M. B. Kadiiska, B. C. Gladen, D. D. Baird, L. B. Graham et al.: Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl(4) poisoning. Free Radic Biol Med. 2005. 38, 711-718.
9. I. Kato, G. Chen, Z. Djuric: Non-steroidal anti-inflammatory drug (NSAID) use and levels of a lipid oxidation marker in plasma and nipple aspirate fluids. Breast Cancer Res Treat. 2006, 97, 145-148.
10. O. Pepicelli, E. Fedele, M. Berardi, M. Raiteri, G. Levi, A. Greco, M. A. Ajmone-Cat, L. Minghetti: Cyclo-oxygenase-1 and -2 differently contribute to prostaglandin E2 synthesis and lipid peroxidation after in vivo activation of N-methyl-D-aspartate receptors in rat hippocampus. J Neurochem. 2005, 93, 1561-1567.
11. A. Dey, C. Maric, W. H. Kaesemeyer, C. Z. Zaharis, J. Stewart, J. S. Pollock, J. D. Imig: Rofecoxib decreases renal injury in obese Zucker rats. Clin. Sci. 2004, 107, 561-570.
12. D. F. Taber, J. D. Morrow, L. J. Roberts 2nd: A nomenclature system for the isoprostanes. Prostaglandins. 1997, 53, 63-67.
13. J. Rokach, S. P. Khanapure, S. W. Hwang, M. Adiyaman, J. A. Lawson, G. A. FitzGerald: Nomenclature of isoprostanes, a proposal. Prostaglandins. 1997, 54, 853-873.
14. R. J. Waugh, R. C. Murphy: Mass spectrometric analysis of four regioisomers of F2-isoprostanes formed by free radical oxidation of arachidonic acid. J Am Soc Mass Spectrom. 1996, 7, 490-499.
15. R. J. Waugh, J. D. Morrow, L. J. Roberts 2nd, R. C. Murphy: Identification and relative quantitation of F2-isoprostane regioisomers formed in vivo in the rat. Free Radic Biol Med. 1997, 23, 943-954.
16. J. D. Morrow, J. A. Awad, H. J. Boss, I. A. Blair, L. J. Roberts, 2nd: Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA. 1992, 89, 10721-10725.
17. D. M. Stafforini, J. R. Sheller, T. S. Blackwell, A. Sapirstein, F. E. Yull, T. M. McIntyre, J. V. Bonventre, S. M. Prescott, L. J. Roberts 2nd: Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem. 2006, 281, 4616-4623.
18. T. J. Montine, J. F. Quinn, D. Milatovic, L. C. Silbert, T. Dang, S. Sanchez, E. Terry, L. J. Roberts 2nd, J. A. Kaye, J. D. Morrow: Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol. 2002, 52, 175-179.
19. K. Moore: Isoprostanes and the liver. Chem Phys Lipids. 2004, 128, 125-133.
20. L. J. Roberts 2nd, K. P. Moore, W. E. Zackert, J. A. Oates, J. D. Morrow: Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2alpha in humans. J Biol Chem. 1996, 271, 20617-20620.
21. Y. Liang, P. Wei, R. W. Duke, P. D. Reaven, S. M. Harman, R. G. Cutler, C. B. Heward: Quantification of 8-iso-prostaglandin-F(2alpha) and 2,3-dinor-8-iso-prostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry. Free Radic Biol Med. 2003, 34, 409-418.
22. E. Granstrom, B. Samuelsson: The structure of a urinary metabolite of prostaglandin F2a in man. J Am Chem Soc. 1969, 91, 3398-400.
23. E. Granstrom, B. Samuelsson: On the metabolism of prostaglandin F2 in female subjects. II. Structures of six metabolites. J Biol Chem. 1971, 246, 7470-7485.
24. E. Granstrom, B. Samuelsson: On the metabolism of prostaglandin F-2-alpha in female subjects. J Biol Chem. 1971, 246, 5254-5263.
25. J. D. Morrow, T. A. Minton, L. J. Roberts 2nd: The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins. 1992, 44, 155-163.
26. X. Hou, L. J. Roberts, II, D. F. Taber, J. D. Morrow, K. Kanai, F. Gobeil, Jr., M. H. Beauchamp, S. G. Bernier, G. Lepage, D. R. Varma, S. Chemtob: 2,3-Dinor-5,6-dihydro-15-F2t-isoprostane, a bioactive prostanoid metabolite. Am J Physiol Regul Integr Comp Physiol. 2001, 281, R391-400.
27. M. Tang, T. Cyrus, Y. Yao, L. Vocun, D. Pratico: Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2alpha-III: evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation. 2005, 112, 2867-2874.
28. D. W. Shineman, B. Zhang, S. N. Leight, D. Pratico, V. M. Lee: Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice. J Neurosci. 2008, 28, 4785-4794.
29. R. G. Salomon, D. B. Miller: Levuglandins, isolation, characterization, and total synthesis of new secoprostanoid products from prostaglandin endoperoxides. Adv Prostaglandin Thromboxane Leukot Res. 1985, 15, 323-326.
30. J. D. Morrow, T. A. Minton, C. R. Mukundan, M. D. Campbell, W. E. Zackert, V. C. Daniel, K. F. Badr, I. A. Blair, L. J. Roberts 2nd: Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. J Biol Chem. 1994. 269, 4317-4326.
31. J. D. Morrow, J. A. Awad, A. Wu, W. E. Zackert, V. C. Daniel, L. J. Roberts 2nd: Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo. J Biol Chem. 1996, 271, 23185-23190.
32. R. G. Salomon, G. Subbanagounder, U. Singh, J. O'Neil, H. F. Hoff: Oxidation of low-density lipoproteins produces levuglandin-protein adducts. Chem Res Toxicol. 1997, 10, 750-759.
33. C. J. Brame, R. G. Salomon, J. D. Morrow, L. J. Roberts 2nd: Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. J Biol Chem. 1999, 274, 13139-13146.
34. H. Yin, J. D. Morrow, N. A. Porter: Identification of a novel class of endoperoxides from arachidonate autoxidation. J Biol Chem. 2004, 279, 3766-3776.
35. M. Hecker, V. Ullrich: On the mechanism of prostacyclin and thromboxane A2 biosynthesis. J Biol Chem. 1989, 264, 141-150.
36. C. J. Brame, O. Boutaud, S. S. Davies, T. Yang, J. A. Oates, D. Roden, L. J. Roberts, 2nd: Modification of proteins by isoketal-containing oxidized phospholipids. J Biol Chem. 2004, 279, 13447-13451.
37. T. J. Montine, K. S. Montine, E. E. Reich, E. S. Terry, N. A. Porter, J. D. Morrow: Antioxidants significantly affect the formation of different classes of isoprostanes and neuroprostanes in rat cerebral synaptosomes. Biochem Pharmacol. 2003, 65, 611-617.
38. S. S. Davies, V. Amarnath, C. J. Brame, O. Boutaud, L. J. Roberts, 2nd: Measurement of chronic oxidative and inflammatory stress by quantification of isoketal/levuglandin gamma-ketoaldehyde protein adducts using liquid chromatography tandem mass spectrometry. Nat Protoc. 2007, 2, 2079-2091.
39. E. Poliakov, M. L. Brennan, J. Macpherson, R. Zhang, W. Sha, L. Narine, R. G. Salomon, S. L. Hazen: Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo. FASEB J. 2003, 17, 2209-2220.
40. R. G. Salomon, E. Batyreva, K. Kaur, D. L. Sprecher, M. J. Schreiber, J. W. Crabb, M. S. Penn, A. M. DiCorletoe, S. L. Hazen, E. A. Podrez: Isolevuglandin-protein adducts in humans: products of free radical-induced lipid oxidation through the isoprostane pathway. Biochim Biophys Acta. 2000, 1485, 225-235.
41. E. E. Reich, W. E. Zackert, C. J. Brame, Y. Chen, L. J. Roberts 2nd, D. L. Hachey, T. J. Montine, J. D. Morrow: Formation of novel D-ring and E-ring isoprostane-like compounds (D4/E4-neuroprostanes) in vivo from docosahexaenoic acid. Biochemistry. 2000, 39, 2376-2383.
42. N. Bernoud-Hubac, S. S. Davies, O. Boutaud, T. J. Montine, L. J. Roberts 2nd: Formation of highly reactive gamma-ketoaldehydes (neuroketals) as products of the neuroprostane pathway. J Biol Chem. 2001, 276, 30964-30970.
43. E. E. Reich, K. S. Montine, M. D. Gross, L. J. Roberts 2nd, L. L. Swift, J. D. Morrow, T. J. Montine: Interactions between apolipoprotein E gene and dietary alpha-tocopherol influence cerebral oxidative damage in aged mice. J Neurosci. 2001, 21, 5993-5999.
44. E. E. Reich, W. R. Markesbery, L. J. Roberts, 2nd, L. L. Swift, J. D. Morrow, T. J. Montine: Quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Adv Exp Med Biol. 2001, 500, 253-256.
45. K. S. Montine, J. F. Quinn, J. Zhang, J. P. Fessel, L. J. Roberts 2nd, J. D. Morrow, T. J. Montine: Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids. 2004, 128, 117-124.
46. D. Milatovic, Y. Zhang, S. J. Olson, K. S. Montine, L. J. Roberts 2nd, J. D. Morrow, T. J. Montine, T. S. Dermody, T. Valyi-Nagy: Herpes simplex virus type 1 encephalitis is associated with elevated levels of F2-isoprostanes and F4-neuroprostanes. J Neurovirol. 2002, 8, 295-305.
47. J. P. Fessel, N. A. Porter, K. P. Moore, J. R. Sheller, L. J. Roberts II: Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc Natl Acad Sci USA. 2002, 99, 16713-16718.
48. J. P. Fessel, C. Hulette, S. Powell, L. J. Roberts 2nd, J. Zhang: Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem. 2003, 85, 645-650.
49. G. L. Milne, S. C. Sanchez, E. S. Musiek, J. D. Morrow: Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc. 2007, 2, 221-226.
50. L. J. Roberts 2nd, T. J. Montine, W. R. Markesbery, A. R. Tapper, P. Hardy, S. Chemtob, W. D. Dettbarn, J. D. Morrow: Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem. 1998, 273, 13605-13612.
51. J. Proudfoot, A. Barden, T. A. Mori, V. Burke, K. D. Croft, L. J. Beilin, I. B. Puddey: Measurement of urinary F2-isoprostanes as markers of in vivo lipid peroxidation - A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem. 1999, 272, 209-215.
52. J. Bessard, J.-L. Cracowski, F. Stanke-Labesque, G. Bessard: Determination of isoprostaglandin F2[alpha] type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay. J Chromatogr B Biomed Sci Appl. 2001, 754, 333-343.
53. D. M. Sasaki, Y. Yuan, K. Gikas, K. Kanai, D. Taber, J. D. Morrow, L. J. Roberts 2nd, D. M. Callewaert: Enzyme immunoassays for 15-F2T isoprostane-M, an urinary biomarker for oxidant stress. Adv Exp Med Biol. 2002, 507, 537-541.
54. D. Il'yasova, J. D. Morrow, A. Ivanova, L. E. Wagenknecht: Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15-F2t- isoprostane. Ann Epidemiol. 2004, 14, 793-797.
55. Z. Wang, G. Ciabattoni, C. Creminon, J. Lawson, G. A. Fitzgerald, C. Patrono, J. Maclouf: Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther. 1995, 275, 94-100.
56. P. Montuschi, E. Ragazzoni, S. Valente, G. Corbo, C. Mondino, G. Ciappi, G. Ciabattoni: Validation of 8-isoprostane and prostaglandin E(2) measurements in exhaled breath condensate. Inflamm Res. 2003, 52, 502-507.
57. P. Montuschi, C. Mondino, P. Koch, P. J. Barnes, G. Ciabattoni: Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J Allergy Clin Immunol. 2006, 118, 347-353.
58. Z. Mallat, T. Nakamura, J. Ohan, G. Leseche, A. Tedgui, J. Maclouf, R. C. Murphy: The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest. 1999, 103, 421-427.
59. H. Li, J. A. Lawson, M. Reilly, M. Adiyaman, S.-W. Hwang, J. Rokach, G. A. FitzGerald: Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F2-isoprostanes in human urine. Proc Natl Acad Sci USA. 1999, 96, 13381-13386.
60. M. H. Shishehbor, R. Zhang, H. Medina, M.-L. Brennan, D. M. Brennan, S. G. Ellis, E. J. Topol, S. L. Hazen: Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med. 2006, 41, 1678-1683.
61. S. S. Davies, W. Zackert, Y. Luo, C. C. Cunningham, M. Frisard, L. J. Roberts 2nd: Quantification of dinor, dihydro metabolites of F2-isoprostanes in urine by liquid chromatography/tandem mass spectrometry. Anal Biochem. 2006, 348, 185-191.
62. A. K. Saenger, T. J. Laha, M. J. Edenfield, S. M. H. Sadrzadeh: Quantification of urinary 8-iso-PGF2[alpha] using liquid chromatography-tandem mass spectrometry and association with elevated troponin levels. Clin Biochem. 2007, 40, 1297-1304.
63. W. Yan, G. D. Byrd, M. W. Ogden: Quantitation of isoprostane isomers in human urine from smokers and non-smokers by LC-MS/MS. J Lipid Res. 2007, 48, 1607-1617.
64. B. Zhang, K. Saku: Control of matrix effects in the analysis of urinary F2-isoprostanes using novel multidimensional solidphase extraction and LC-MS/MS. J Lipid Res. 2007, 48, 733-744.
65. A. W. Taylor, R. S. Bruno, B. Frei, M. G. Traber: Benefits of prolonged gradient separation for high-performance liquid chromatography-tandem mass spectrometry quantitation of plasma total 15-series F2-isoprostanes. Anal Biochem. 2006, 350, 41-51.
66. M. Masoodi, A. Nicolaou: Lipidomic analysis of twenty-seven prostanoids and isoprostanes by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006, 20, 3023-3029.